Table 2

Anti-MCV, anti-CCP and RF levels in patients with ExRA, individual ExRA manifestations and RA controls

N†Anti-MCV (U/ml)Anti-CCP (U/ml)RF (IU/ml)
MedianIQRMedianIQRMedianIQR
ExRA35333*116–93642776–1516245###94–604
Major cutaneous vasculitis9388**236–28571171⊥⊥458–1420413##150–1450
Felty's syndrome51617***1221–163058087⊥⊥⊥1999–14686299#117–1043
Neuropathy420957–321663129–108715843–1026
Pericarditis10466211–77833964–1769276#83–359
Pleuritis1016523–39687ND-27115635–495
Controls with RA70‡20310–514169ND§-113373ND-165
  • *p=0.02, **p=0.047 and ***p=0.004 as compared with RA controls. p=0.09, ⊥⊥p=0.02, ⊥⊥⊥p=0.005, #p<0.05, ##p=0.002 and ###p=0.0002 as compared with RA controls, as previously reported.3

  • †There were two patients with major cutaneous vasculitis and neuropathy, and one patient with Felty's syndrome and pericarditis.

  • ‡Data on 67 controls for anti-MCV.

  • §23/31 anti-CCP negative controls with RA and 6/8 anti-CCP negative cases with ExRA did not have any determinable anti-CCP antibodies.

  • CCP, cyclic citrullinated peptides; ExRA, extra-articular RA; MCV, modified citrullinated vimentin; ND, not determinable; RF, rheumatoid factor.